 NEWTOWN, Pa., Aug. 17, 2021 GLOBE NEWSWIRE -- Helius Medical Technologies, Inc. Nasdaq:HSDT TSX:HSM Helius or the Company, a neurotech company focused on neurological wellness, today announced that it has received Breakthrough Designation from the U.S. Food and Drug Administration FDA for its PoNSTM device with the proposed indication for use as a temporary treatment of dynamic gait and balance deficits due to symptoms from stroke, to be used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over. 